05:07 PM EDT, 10/01/2024 (MT Newswires) -- Myriad Genetics ( MYGN ) said Tuesday that the US Patent and Trademark Office has issued a third patent that will boost the company's ability to deliver a molecular residual disease assay to market.

The claims cover methods that generate ultra-sensitive detection of tumor-specific mutations in circulating tumor DNA, Myriad said.

It obtained two complementary patents on foundational platform MRD technology and cell-free DNA preparation methods earlier.